Skip to content
Infectious Disease

Resources for Health Care Providers

*Suspected or confirmed active tuberculosis disease is a reportable condition in Alaska.*  
Cases should be reported to the Alaska TB Program within 2 business days.  Please call the Section of Epidemiology at 907-269-8000, or complete the appropriate report form and fax to 907-561-4239.
*NOTICE of PRI​FTIN® (RIFAPENTINE) impurity issue 7-1-20*
In June 2020 Sanofi alerted the Division of Tuberculosis Elimination, other health agencies, and stakeholders worldwide about a newly detected impurity in Priftin®. The impurity, 1-cyclopentyl-4-nitrosopiperazine, is a nitrosamine and a potential carcinogen.  Read more at the links below.

Letter to Alaska providers/public health nurses​​​

Information from CDC​

Provider Toolkit


The USPSTF recommends screening for latent TB infection (LTBI) in populations at increased risk.  Finding and treating patients with LTBI is key to controlling the TB epidemic.

IGRA (blood) testing is​ now approved for all persons>2 years of age and has some advantages over TST (skin test), especially in foreign-born persons who may have received BCG vaccination in the past.
Treatment for LTBI
There are now shorter-course regimens which make LTBI treatment easier.  It is very important to rule out active TB disease prior to starting treatment for LTBI.
Treatment for Active TB
Patient Education

For Civil Surgeons

TB Reports/Bulletins